Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion


Warning: Array to string conversion in /var/www/vhosts/dev2.tgtherapeutics.com/httpdocs/wp-content/plugins/document-library-pro/dependencies/barn2/document-library-core/src/Document.php on line 665

Warning: Array to string conversion in /var/www/vhosts/dev2.tgtherapeutics.com/httpdocs/wp-content/plugins/document-library-pro/dependencies/barn2/document-library-core/src/Document.php on line 665
Drug Category: Array
Conference Category: Array
Lead Author: Lovett-Racke A, Fox E et al.
Published Date: 28/04/2017
Download Link: https://dev2.tgtherapeutics.com/wp-content/uploads/2019/03/Final%20AAN%20RMS%202017.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top